ZOLINZA vorinostat
Drug Class
Histone deacetylase inhibitor组蛋白去乙酰化酶抑制剂
Mechanism
Inhibits Class I and II HDACs, inducing histone accumulation of acetyl groups to cause chromatin remodeling and tumor cell apoptosis.抑制 I 类和 II 类 HDAC，导致乙酰基在组蛋白上积累，引起染色质重塑并诱导肿瘤细胞发生凋亡。
Approved Indication
Treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent or recurrent disease on or following two systemic therapies.治疗既往接受过两种系统治疗后病情进展、持续或复发的皮肤 T 细胞淋巴瘤 (CTCL) 患者的皮肤表现。
What This Means For Patients
Zolinza (vorinostat) is an oral epigenetic modifier that acts as an HDAC inhibitor for cutaneous T-cell lymphoma (CTCL). It helps control and reverse the skin lesions caused by CTCL in advanced cases. It is available under the special-import policy in the Hainan Boao Lecheng pilot zone.伏立诺他（Zolinza）是一种口服表观遗传修饰剂，属于组蛋白去乙酰化酶（HDAC）抑制剂类，用于治疗皮肤 T 细胞淋巴瘤（CTCL）。它有助于控制和逆转晚期病例中由 CTCL 引起的皮肤病变。该药物已通过先行区特许进口政策引入博鳌乐城。
Regulatory Approvals
- FDA — approved (2006) — label
Pivotal Clinical Evidence
- Study 001 — Olsen et al., J Clin Oncol 2007 (NCT00097929) — DOI
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.